Duloxetine prevents bortezomib and paclitaxel large-fiber chemotherapy-induced peripheral neuropathy (LF-CIPN) in sprague dawley rats
Molecular Pain · 2023-06 · 19
DOI: 10.1177/17448069231185694 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pain, online erschienen am 21.06.2023. Verfasst von Niloufar Mansooralavi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral & Maxillofacial Surgery, Division of Neuroscience, UCSF Pain and Addiction Research Center, University of California at San Franci…. Hauptthemen laut MEDLINE: Peripheral Nervous System Diseases, Antineoplastic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating, treatment-limiting, side-effect of several classes of chemotherapy drugs. While negatively impacting oncology patients’ quality of life, chemotherapy-induced large-fiber (LF) neuropathy is amongst the least well understood components of CIPN, and one for which there is currently no established therapy. Preliminary clinical observations have led to the suggestion that Duloxetine, which is used for the treatment of pain associated with small-fiber CIPN (SF-CIPN), may be effective against LF-CIPN. In the present experiments we developed a model of LF-CIPN and studied the effect of Duloxetine on LF-CIPN induced by two neurotoxic chemotherapy agents: the proteasome inhibitor, Bortezomib, a first-line treatment of multiple myeloma; and, the anti-microtubule taxane, Paclitaxel, used in the treatment of solid tumors. Since there are currently no models for selective the study of LF-CIPN, our first aim was to establish a pre-clinical model in the rat. LF-CIPN was evaluated with the Current Perception Threshold (CPT) assay, which uses a high frequency (1000 Hz) electrical stimulus protocol that selectively activates large-fiber myelinated afferents. Our second aim was to use this model to test the hypothesis that Duloxetine can prevent LF-CIPN. We report that Bortezomib and Paclitaxel induce elevation of CPT, compatible with loss of large-fiber function, which are prevented by Duloxetine. Our findings support the clinical observation that Duloxetine may be an effective treatment for the large-fiber CIPN. We also suggest that CPT could be used as a biomarker for LF-CIPN in patients receiving neurotoxic chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral & Maxillofacial Surgery, Division of Neuroscience, UCSF Pain and Addiction Research Center, University of California at San Francisco, San Francisco, CA, USA.
ORCID-Profile: Niloufar Mansooralavi
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Mansooralavi, N., Khomula, E. V., & Levine, J. D. (2023). Duloxetine prevents bortezomib and paclitaxel large-fiber chemotherapy-induced peripheral neuropathy (LF-CIPN) in sprague dawley rats. Molecular Pain, 19. https://doi.org/10.1177/17448069231185694
Vancouver
Mansooralavi N, Khomula EV, Levine JD. Duloxetine prevents bortezomib and paclitaxel large-fiber chemotherapy-induced peripheral neuropathy (LF-CIPN) in sprague dawley rats. Molecular Pain. 2023;19. doi:10.1177/17448069231185694
BibTeX
@article{Mansooralavi2023,
author = {Mansooralavi, Niloufar and Khomula, Eugen V and Levine, Jon D},
title = {Duloxetine prevents bortezomib and paclitaxel large-fiber chemotherapy-induced peripheral neuropathy (LF-CIPN) in sprague dawley rats},
journal = {Molecular Pain},
year = {2023},
volume = {19},
doi = {10.1177/17448069231185694}
}
EUVIMED